Multiplex planar microarrays for disease prognosis, diagnosis and theranosis

Advanced diagnostic methods and algorithms for immune disorders provide qualitative and quantitative multiplex measurement for pre-clinical prognostic and clinical diagnostic biomarkers specific for diseases.Choice of therapy is confirmed by modulating diagnostic efficacy of companion, theranotic drug concentrations.Assay methods identify, monitor and manage autoimmune diseases, or risk thereof, in subjects who have,or who are related to individuals with autoimmune disease. These same diagnostic protocols also integratequalitative and quantitative assay test protocol designs for responder patient assessment, risk analysis and management of disease when integrating multiplex planar microarray diagnostic tests, patient theranostic companion diagnostic methods and test panels for simultaneous assessment and management of dysimmune and inflammatory disorders, autoimmunity, allergy and cancer. Proprietary assay methods are provided to identify, monitor and manage dysimmune conditions, or risk thereof, in subjects with pathological alterations in the immune system, or who are related to individuals with these conditions. The protocols can be used for confirmatory testing of subjects who exhibit symptoms of dysimmunity, as well as subjects who are apparently healthy and do not exhibit symptoms of altered immune function. The protocols also provide for methods of determining whether a subject has, is at risk for, or is a candidate for disease therapy, guided by companion diagnosis and immunosuppressive therapy, as well as therapeutic drug monitoring and theranostic testing of disease biomarkers in response to immunoabsorption therapy. The multiplex test panels provide the components that are integral for performing the methods to recognized clinical standards.

Magnetic lipid nanovehicles synergize the controlled thermal release of chemotherapeutics with magnetic ablation while enabling non-invasive monitoring by MRI for melanoma theranostics

Nowadays,a number of promising strategies are being developed that aim at combining diagnostic and therapeutic capabilities into clinically effective formulations.Thus,the combination of a modified release provided by an organic encapsulation and the intrinsic physico-chemical properties from an inorganic counterpart opens new perspectives in biomedical applications.Herein,a biocompatible magnetic lipid nanocomposite vehicle was developed through an efficient,green and simple method to simultaneously incorporate magnetic nanoparticles and an anticancer drug(doxorubicin)into a natural nano-matrix.The theranostic performance of the final magnetic formulation was validated in vitro and in vivo,in melanoma tumors.The systemic administration of the proposed magnetic hybrid nanocomposite carrier enhanced anti-tumoral activity through a synergistic combination of magnetic hyperthermia effects and antimitotic therapy,together with MRI reporting capability.The application of an alternating magnetic field was found to play a dual role,(i)acting as an extra layer of control(remote,on-demand)over the chemotherapy release and(ii)inducing a local thermal ablation of tumor cells.This combination of chemotherapy with thermotherapy establishes a synergistic platform for the treatment of solid malignant tumors under lower drug dosing schemes,which may realize the dual goal of reduced systemic toxicity and enhanced anti-tumoral efficacy.